Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)
Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)
The purpose of this post-marketing surveillance study is to collect and assess information
 retrospectively on safety and effectiveness of fondaparinux injection in patients with venous
 thromboembolism (VTE) whose body weight is 100 kilograms (kg) or more, or to whom
 fondaparinux was injected 10 mg/day.

 ("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)
Inclusion Criteria:

 -  Patients with acute pulmonary thromboembolism or acute deep venous thrombosis

 -  Fondaparinux injection must be prescribed for the first time

 Exclusion Criteria:

 -  Not applicable